

washed with H₂O, and dried to 0.35 g. of white needles, m.p. 288~289° (decomp.). *Anal.* Calcd. for C₁₂H₁₀N₅S₃: C, 39.78; H, 2.87. Found: C, 39.98; H, 3.01.

5-Amino-7-methylthio-s-triazolo[2,3-*a*]pyrimidine (XXIV)—a) A mixture of 2.0 g. of (XXI) and 30 cc. of EtOH-NH₃ was heated in a sealed tube at 150~160° for 10 hr. The reaction mixture was evaporated to dryness, the residue was dissolved in dil. HCl, filtered with charcoal, and the filtrate was neutralized with dil. NaOH to form 1.3 g. of white crystalline product. Recrystallization from EtOH gave colorless needles, m.p. 230~231°. *Anal.* Calcd. for C₆H₇N₅S: C, 39.77; H, 3.89; N, 38.65. Found: C, 40.06; H, 4.18; N, 38.58.

b) A mixture of 0.4 g. of (X) and 15 cc. of EtOH-NH₃ was reacted as above and the product was recrystallized from EtOH to 0.35 g. of colorless needles, m.p. 230~231°, which showed no depression on admixture with (XXIV), prepared by the method (a).

The author is deeply grateful to Dr. K. Takeda, Director of this Laboratory, and to Dr. H. Kanō of this Laboratory, for their helpful guidance and encouragement. Thanks are also due to Messrs. H. Miyazaki and I. Tanaka for ultraviolet and infrared spectral measurements, and to the members of the Analysis Room of this Laboratory for elemental analysis.

Summary

The products of the condensation of 5-amino-*s*-triazole (I) with ethyl malonate, ethyl cyanoacetate, and methyl ethoxycarbonyldithioacetate were proved to be respectively 5,7-dihydroxy-, 5-hydroxy-7-amino-, and 5-hydroxy-7-mercapto-*s*-triazolo[2,3-*a*]pyrimidines (II, III, and IV). (II) was converted into the 5,7-dichloro derivative (VI), and the reactivity of the two halogens in (VI) towards the usual nucleophilic reagents was examined. (IV) was also transformed into the 5-chloro-7-methylthio derivative (XXI), which was converted into 5-substituted 7-methylthio derivatives by nucleophilic substitution. Ultraviolet absorption spectra of 5-substituted and 7-substituted *s*-triazolo[2,3-*a*]pyrimidines were compared.

(Received October 17, 1960)

UDC 615.771.7 : 547.859.3

126. Yasuo Makisumi: Synthesis of Potential Anticancer Agents. V.*² 6-Halo-*s*-triazolo[2,3-*a*]pyrimidines.

(Research Laboratory, Shionogi & Co., Ltd.*¹)

In the previous paper¹⁾ of this series, it was reported that the reaction of 5-methyl-7-hydroxy-*s*-triazolo[2,3-*a*]pyrimidine (I) with phosphoryl chloride gave 5-methyl-7-chloro derivative (II), but that the reaction of (I) with a mixture of phosphorus pentachloride and phosphoryl chloride resulted in the formation of the 5-methyl-6,7-dichloro derivative (IIa). In the latter reaction, it was assumed that the 6-position of (I) was activated for electrophilic substitution by the hydroxyl group at 7-position and consequently was chlorinated with phosphorus pentachloride into the 5-methyl-6-chloro-7-hydroxy derivative (Ia) and then chlorination of the hydroxyl group of (Ia) followed to give (IIa). In order to prove this assumption, the halogenation of 7-hydroxy- or 7-amino-*s*-triazolo[2,3-*a*]pyrimidine and its 5-methyl derivative with chlorine or bromine was carried out, and the expected 6-halo derivatives were obtained.^{1,2)}

*¹ Fukushima-ku, Osaka (牧角徳夫).

*² Part IV: This Bulletin, 9, 801 (1961).

1) H. Kanō, Y. Makisumi, S. Takahashi, M. Ogata: *Ibid.*, 7, 903 (1959).

2) Y. Makisumi, H. Kanō: *Ibid.*, 7, 907 (1959).




Chart 1.

The present study deals with the halogenation of the derivatives of *s*-triazolo[2,3-*a*]pyrimidine, and the direct synthesis of 6-halo-*s*-triazolo[2,3-*a*]pyrimidines.

s-Triazolo[2,3-*a*]pyrimidine (III) and its 5-methyl derivative (IV) were halogenated by the action of chlorine or bromine in glacial acetic acid at room temperature to corresponding monohalogenated products (IIIa, IIIb, IVa, and IVb). These compounds were identical with 6-halo- and 5-methyl-6-halo-*s*-triazolo[2,3-*a*]pyrimidines which were obtained by catalytic reduction of 6-halo-7-chloro-*s*-triazolo[2,3-*a*]pyrimidines³⁾ (Va and Vb) and their 5-methyl derivatives¹⁾ (IIa and IIb). However, 5,7-dimethyl-*s*-triazolo[2,3-*a*]pyrimidine³⁾ (VI) did not react with chlorine or bromine under the same condition.

These experiments suggest that the reaction proceeds by the following mechanism. In the *s*-triazolo[2,3-*a*]pyrimidine (III) and its 5-methyl derivative (IV), their 6-positions are activated towards electrophilic substitution by the -M effect of the ring-nitrogen at the 8-position and therefore (III) and (IV) were halogenated into 6-halogen derivatives (IIIa, IIIb, IVa, and IVb), while no reaction occurred in the 5,7-dimethyl derivative (VI), owing to steric hindrance of the two methyl groups.

Reaction of 5-hydroxy-7-amino derivative*² (VII) and 5,7-dihydroxy derivative*² (VIII) with bromine in glacial acetic acid gave 6-bromo derivatives (VIIa and VIIIb) but the reaction of (VII) and (VIII) with chlorine did not produce 6-chloro derivatives (VIIa and VIIIa), resulting in the formation of a substance, C₄H₄ON₄Cl₂, m.p. 217° (decomp.) (IX), and half of the original materials (VII and VIII) was recovered. (IX) was identified with 5-dichloroacetamido-*s*-triazole obtained by reaction of 5-amino-*s*-triazole (X) with dichloroacetyl chloride. In this reaction, the use of two moles of chlorine for (VII) and (VIII) gave (IX) in a good yield without recovery of the original materials (VII and VIII).

These abnormal reactions seem to be the result of the following mechanism. 6-Position of (VII) or (VIII) is strongly activated by the two adjacent hydroxyl or amino groups which could take keto and imino form (VII' and VIII'), so that the chlorination gave 6,6-dichloro derivatives (VIIc and VIIIc), replacing the two hydrogen atoms at 6-position. Ring cleavage between 7- and 8-position to (XI) and subsequent decomposition of (XI) would produce (IX). On the other hand, in the case of bromination of (VII) and (VIII), the replace-

3) C. Bülow, K. Haas : Ber., 42, 4638 (1909); K. Shirakawa : Yakugaku Zasshi, 79, 903 (1959).

ment of two atoms of bromine at 6-position could not occur due to a large volume of the bromine atom and 6-bromo derivatives (VIIb and VIIIb) were obtained in a good yield.

Thus, it was clarified that the 6-position of *s*-triazolo[2,3-*a*]pyrimidines is readily halogenated with chlorine or bromine, except in a few cases.




Chart 2.

It was also reported in the previous paper¹⁾ that the condensation of ethyl 2-haloacetoacetate with (X) gave 5-methyl-6-halo-7-hydroxy-*s*-triazolo[2,3-*a*]pyrimidines (Ia and Ib). Attempts to synthesize 5,7-disubstituted 6-halo-*s*-triazolo[2,3-*a*]pyrimidines were carried out by the same method.

Treatment of 3-halopentane-2,4-dione with (X) in ethanol at boiling temperature for 8 hours gave 5,7-dimethyl-6-chloro-*s*-triazolo[2,3-*a*]pyrimidine (VIa) in a good yield, but




Chart 3.

TABLE I. Ultraviolet Absorption Spectra of 6-Halo-s-triazolo[2,3-a]pyrimidines

Compd. No.	R ₁	R ₂	X	$\lambda_{\text{max}}^{\text{EtOH}}$ m μ (log ϵ)		$\Delta\lambda$ (m μ)
				λ_{max}	(log ϵ)	
(III)	H	H	H	273	(3.57)	
(IIIa)	"	"	Cl	290	(3.54)	+17
(IIIb)	"	"	Br	291.5	(3.51)	+18.5
(IV)	CH ₃	"	H	272	(3.59)	
(IVa)	"	"	Cl	286	(3.58)	+14
(IVb)	"	"	Br	288	(3.59)	+16
(II)	"	Cl	H	275	(3.71)	
(IIa)	"	"	Cl	288	(3.68)	+13
(IIb)	"	"	Br	291	(3.70)	+16
(VI)	"	CH ₃	H	271	(3.70)	
(VIa)	"	"	Cl	284.5	(3.66)	+13.5
(VII)	OH	NH ₂	H	269	(4.13)	
(VIIa)	"	"	Cl	277.5	(4.07)	+8.5
(VIIb)	"	"	Br	279	(4.07)	+10
(VIII)	"	OH	H	261	(4.14)	
(VIIIa)	"	"	Cl	273	(4.11)	+12
(VIIIb)	"	"	Br	273.5	(4.03)	+12.5
	H	NH ₂	H	263.5	(3.72) ^{a)}	
	"	"	Cl	261	(3.69)	
	"	"	Br	262	(3.72)	+12
	CH ₃	"	H	258	(3.71) ^{a)}	
	"	"	Cl	260	(3.66)	+11
	"	"	Br	261	(3.66)	+10.5
	H	OH	H	242	(3.67)	
	"	"	Cl	251	(3.72)	+19.5
	"	"	Br	252.5	(3.74)	+21.5
	CH ₃	"	H	240	(3.62) ^{a)}	
	"	"	Cl	251.5	(3.69)	+17
	"	"	Br	252.5	(3.73)	+18.5

a) shoulder

the 6-bromo derivative (VIb) was not obtained owing to resinification. Ethyl halocyanacetate and ethyl halomalonate similarly reacted with (X) in the presence of sodium ethoxide in ethanol to give 5-hydroxy-6-chloro-7-amino derivative (VIIa) and 6-chloro-5,7-dihydroxy derivative (VIIa), both in a poor yield, but 6-bromo derivatives (VIIb and VIIb) were not obtained owing to resinification.

Ultraviolet absorption spectra of 6-halo-*s*-triazolo[2,3-*a*]pyrimidines were measured. These spectra showed similar curves to the spectra of the corresponding original compounds and the introduction of halogen at 6-position produced a bathochromic shift to the extent of about 10~20 m μ and a little hypochromic effect.

Biological details of these compounds will be published elsewhere.

Experimental*³

6-Chloro-*s*-triazolo[2,3-*a*]pyrimidine (IIIa)—a) To a solution of 1.2 g. of (III) in 12 cc. of AcOH, 0.7 g. of Cl₂ was absorbed. After stirring at room temperature for 3 hr., the solvent was evaporated to dryness in a reduced pressure and the residue was recrystallized from H₂O to 0.9 g. of colorless needles, m.p. 174~175°. *Anal.* Calcd. for C₅H₃N₄Cl: C, 38.87; H, 1.97; N, 36.27. Found: C, 38.99; H, 2.22; N, 36.15.

b) To a solution of 0.45 g. of 6,7-dichloro-*s*-triazolo[2,3-*a*]pyrimidine (Va) in 45 cc. of dehyd. EtOH, 0.2 g. of 5% Pd-C and 0.2 g. of Na₂CO₃ were added and the mixture was shaken at room temperature in H₂ stream. A theoretical uptake of 1 mole of H₂ occurred during about 1 hr. After removal of the catalyst, the filtrate was evaporated to dryness, 10 cc. of H₂O was added to the residue, and the insoluble crystals were collected and recrystallized from H₂O to 0.35 g. of colorless needles, m.p. 174~175°, alone and in admixture with the sample prepared by method (a). *Anal.* Calcd. for C₅H₃N₄Cl: C, 38.87; H, 1.97; N, 36.27. Found: C, 39.24; H, 2.09; N, 36.26.

6-Bromo-*s*-triazolo[2,3-*a*]pyrimidine (IIIb)—a) To a solution of 0.6 g. of (III) in 6 cc. of AcOH, 0.8 g. of Br₂ in 4 cc. of AcOH was added in drops with stirring. After stirring for 3 hr., the solvent was evaporated *in vacuo* and the residue was recrystallized from H₂O to 0.6 g. of colorless pillars, m.p. 183~184°. *Anal.* Calcd. for C₅H₃N₄Br: C, 30.17; H, 1.52; N, 28.45. Found: C, 30.50; H, 1.81; N, 28.21.

b) To a solution of 1 g. of 6-bromo-7-chloro-*s*-triazolo[2,3-*a*]pyrimidine (Vb) in 100 cc. of dehyd. EtOH, 0.4 g. of Na₂CO₃ and 0.4 g. of 5% Pd-C were added and the mixture was submitted to reduction at ordinary temperature and pressure. After 1 mole of H₂ was absorbed, the reaction mixture was treated by the same method as for (IIIa) in (a) and the resulting product was recrystallized from H₂O to 0.5 g. of colorless pillars, m.p. 183~184°, alone and in admixture with the sample (IIIb) prepared by the method (a).

5-Methyl-6-chloro-*s*-triazolo[2,3-*a*]pyrimidine (IVa)—To a solution of 1.34 g. of (IV) in 20 cc. of AcOH, 0.7 g. of Cl₂ was absorbed. After stirring at room temperature for 3 hr., the solvent was evaporated to dryness in a reduced pressure, the residue was basified with dil. NH₄OH, extracted with CHCl₃, and dried over Na₂SO₄. The extract was evaporated and the resulting crystals were recrystallized from ligroine to 1.3 g. of colorless pillars, m.p. 130~131°, alone and in admixture with the authentic sample of (IVa).¹⁾ *Anal.* Calcd. for C₆H₅N₄Cl: C, 42.74; H, 2.98; N, 33.23. Found: C, 43.02; H, 3.29; N, 33.17.

5-Methyl-6-bromo-*s*-triazolo[2,3-*a*]pyrimidine (IVb)—a) To a solution of 1.34 g. of (IV) in 20 cc. of AcOH, a solution of 1.6 g. of Br₂ in 10 cc. of AcOH was added dropwise with stirring. After stirring for further 3 hr., the reaction mixture was treated by the same method as for (IVa) and the resulting product was recrystallized from ligroine to 1.5 g. of colorless pillars, m.p. 137~138°. *Anal.* Calcd. for C₆H₅N₄Br: C, 33.82; H, 2.36; N, 26.29; Br, 37.50. Found: C, 34.17; H, 2.57; N, 26.05; Br, 37.30.

b) To a solution of 1.24 g. of 5-methyl-6-bromo-7-chloro-*s*-triazolo[2,3-*a*]pyrimidine (IIb) in 100 cc. of dehyd. EtOH, 0.3 g. of 5% Pd-C was added and the mixture was reduced under the same condition as above. After 1 mole of H₂ was absorbed, the reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was basified with dil. NH₄OH and extracted with CHCl₃, which was dried over Na₂SO₄. The solvent was evaporated and the resulting crystals were recrystallized from ligroine to 0.8 g. of colorless pillars, m.p. 137~138°, alone and in admixture with the sample (IVb) prepared by the method (a).

*³ All melting points are uncorrected. Ultraviolet spectra were measured with the Hitachi Recording Spectrophotometer, EPS-2.

5-Hydroxy-6-bromo-7-amino-*s*-triazolo[2,3-*a*]pyrimidine (VIIIb)—To a suspension of 1.5 g. of 5-hydroxy-7-amino-*s*-triazolo[2,3-*a*]pyrimidine (VII) in 30 cc. of AcOH, a solution of 1.6 g. of Br₂ in 10 cc. of AcOH was added in drops with stirring and the reaction mixture was soon decolorized. After stirring at room temperature for further 1 hr., the resulting precipitate was collected, dissolved in dil. NaOH, filtered with charcoal, and the filtrate was acidified with dil. AcOH to 2.2 g. of white crystals. Recrystallization from 50% MeOH gave colorless needles, m.p. above 320°. *Anal.* Calcd. for C₅H₄ON₃Br: C, 26.09; H, 1.74; N, 30.43. Found: C, 26.39; H, 1.85; N, 30.19.

5,7-Dihydroxy-6-bromo-*s*-triazolo[2,3-*a*]pyrimidine (VIIIb)—To a suspension of 3 g. of 5,7-dihydroxy-*s*-triazolo[2,3-*a*]pyrimidine (VIII) in 100 cc. of AcOH, a solution of 3.2 g. of Br₂ in 20 cc. of AcOH was added in drops. After stirring for 30 min., the separated crystals were collected, dissolved in dil. NaOH, filtered with charcoal, and the filtrate was acidified with HCl to 4 g. of white scales, m.p. above 320°. Recrystallization from H₂O gave colorless scales, m.p. above 320°. *Anal.* Calcd. for C₅H₃O₂N₄Br·½H₂O: C, 25.00; H, 1.67; N, 23.33. Found: C, 24.88; H, 1.89; N, 23.10.

5-Dichloroacetamido-*s*-triazole (IX)—To a suspension of 3.4 g. of (X) in 90 cc. of dehyd. benzene, a solution of 9.2 g. of dichloroacetyl chloride in 10 cc. of benzene was added dropwise, the mixture was refluxed for 3 hr., and allowed to stand overnight. The insoluble part was collected by filtration and recrystallized from hydr. EtOH to 0.9 g. of white needles, m.p. 217°(decomp.). *Anal.* Calcd. for C₄H₄ON₄Cl₂: C, 24.63; H, 2.06; N, 28.73. Found: C, 24.90; H, 2.07; N, 28.65.

Reaction of (VII) with Cl₂—To a suspension of 1.5 g. of (VII) in 30 cc. of AcOH, 0.7 g. of Cl₂ was absorbed. After stirring for 2 hr. at room temperature, the insoluble portion was filtered off, the filtrate was evaporated to dryness in a reduced pressure, and the residue was recrystallized from hydr. EtOH to 0.7 g. of white needles (IX), m.p. 217°(decomp.). *Anal.* Calcd. for C₄H₄ON₄Cl₂: C, 24.63; H, 2.06; N, 28.73; Cl, 36.36. Found: C, 24.73; H, 2.03; N, 28.54; Cl, 36.40.

The insoluble portion was dissolved in dil. NaOH, filtered with charcoal, and the filtrate was acidified with AcOH, affording white crystals (0.7 g.), which were recrystallized from hydr. EtOH to colorless prisms, m.p. over 320°, identified with (VII) by infrared spectrum.

Reaction of (VIII) with Cl₂—To a suspension of 1.5 g. of (VIII) in 30 cc. of AcOH, 0.7 g. of Cl₂ was absorbed. The mixture was reacted and treated as above to 0.6 g. of white needles (IX), m.p. 217°(decomp.). *Anal.* Calcd. for C₄H₄ON₄Cl₂: C, 24.63; H, 2.06; N, 28.73. Found: C, 24.77; H, 2.26; N, 28.63.

The insoluble portion (0.65 g.) was recrystallized from hydr. EtOH to colorless needles, m.p. 238°(decomp.), which was identified with (VIII).

5,7-Dimethyl-6-chloro-*s*-triazolo[2,3-*a*]pyrimidine (VIa)—A solution of 5.4 g. of 3-chloropentene-2,4-dione and 3.3 g. of (X) in 15 cc. of EtOH was refluxed for 8 hr. The reaction mixture was concentrated to one-half the original volume, the resulting crystals were collected by filtration, and recrystallized from ligroine to 4.6 g. of colorless pillars, m.p. 101~102°. *Anal.* Calcd. for C₇H₇N₄Cl: C, 46.03; H, 3.86; N, 30.68. Found: C, 46.07; H, 4.13; N, 30.26.

5-Hydroxy-6-chloro-7-amino-*s*-triazolo[2,3-*a*]pyrimidine (VIIa)—To a solution of 1.5 g. of Na in 55 cc. of dehyd. EtOH, 7.3 g. of ethyl chloroacetoacetate and 5.3 g. of (X) were added. The solution was refluxed for 3.5 hr. and colored brown, when the Na salt deposited. After cool, the resulting Na salt was collected by filtration, dissolved in H₂O, filtered with charcoal, and the filtrate was acidified with dil. AcOH to colored crystals. White needles (0.8 g.), m.p. above 320°, of (VIIa) were obtained after the precipitation was repeated. *Anal.* Calcd. for C₅H₄ON₃Cl: C, 32.35; H, 2.15; N, 37.74. Found: C, 32.78; H, 2.47; N, 37.34.

5,7-Dihydroxy-6-chloro-*s*-triazolo[2,3-*a*]pyrimidine (VIIIa)—To a solution of 0.8 g. of Na in 30 cc. of dehyd. EtOH, 6.5 g. of ethyl chloromalonate and 2.8 g. of (X) were added and the solution was refluxed for 6 hr. After cool, the precipitated Na salt was treated as above and the resulting product was recrystallized from hydr. EtOH to 0.5 g. of colorless needles, m.p. above 320°. *Anal.* Calcd. for C₅H₃O₂N₄Cl·½H₂O: C, 30.50; H, 2.04; N, 28.68; Cl, 18.15. Found: C, 30.23; H, 2.43; N, 28.61; Cl, 17.92.

The author expresses his gratitude to Dr. K. Takeda, Director of this Laboratory, and to Dr. H. Kanō of this Laboratory, for their helpful guidance and encouragement. Ultraviolet spectra were measured by Dr. T. Kubota and Mr. I. Tanaka, and elemental analyses were carried out by the members of Analysis Room of this Laboratory, to all of whom the author is indebted.

Summary

Halogenation of *s*-triazolo[2,3-*a*]pyrimidine and its 5-methyl derivative with chlorine or bromine gave the corresponding 6-halo derivative (IIIa, IIIb, IVa, and IVb), but in the

case of 5-hydroxy-7-amino- and 5,7-dihydroxy-*s*-triazolo[2,3-*a*]pyrimidines, reaction of bromine gave 6-bromo derivatives (VIIb and VIIIb) while that of chlorine gave 5-dichloroacetamido-*s*-triazole (IX) instead of 6-chloro derivatives (VIIa and VIIIa). 2-Halo-1,3-dicarbonyl compounds were condensed with 5-amino-*s*-triazole (X) into 6-chloro-*s*-triazolo[2,3-*a*]pyrimidines (VIa, VIIa, and VIIIa), but 6-bromo derivatives were not obtained due to resinification. Ultraviolet spectra of 19 kinds of 6-halo-*s*-triazolo[2,3-*a*]pyrimidines were measured and compared with those of the corresponding original compounds.


(Received October 17, 1960)

UDC 615.771.7 : 547.859.3

127/ Yasuo Makisumi : Synthesis of Potential Anticancer Agents. VI.*²
Reactivity of 6-Bromo-*s*-triazolo[2,3-*a*]pyrimidines.

(Research Laboratory, Shionogi & Co., Ltd.*¹)

In Part III of this series,¹⁾ it was shown that the halogen atom at 7-position of *s*-triazolo[2,3-*a*]pyrimidines reacted readily with nucleophilic reagents, but the halogen atom at 6-position was very resistant to nucleophilic substitutions. For example, 6,7-dihalo-*s*-triazolo[2,3-*a*]pyrimidines reacted with acid or alkali, ammonia, thiourea, and hydrogen iodide to form 7-hydroxy-, 7-amino-, 7-mercapto-, and 7-iodo-6-halo-*s*-triazolo[2,3-*a*]pyrimidines, respectively.



It has been generally concluded that in the pyrimidine series halogens at 5-position of pyrimidines are quite stable and difficult to be displaced by nucleophilic reagents, except in a few cases.

However, Phillips²⁾ has reported that the 5-bromo derivatives of uracil and isocytosine react with several amines to give the corresponding 5-substituted amino derivatives. Barker and co-workers³⁾ have also reported that the 5-bromo derivatives of barbituric acid and 6-aminouracil react with thiourea to give the corresponding derivatives containing sulfur at their 5-position.

These facts suggested the possibility that, in *s*-triazolo[2,3-*a*]pyrimidines, the presence of groups capable of tautomerism at both 5- and 7-positions might activate the halogen at 6-position sufficiently to bring about a reaction. In order to clarify this point, the same reactions were carried out with 6-bromo-*s*-triazolo[2,3-*a*]pyrimidines in the present series of work.

*¹ Fukushima-ku, Osaka (牧角徳夫).

*² Part V : This Bulletin, 9, 808 (1961).

1) Y. Makisumi, H. Kanō : *Ibid.*, 7, 907 (1959).

2) A.P. Phillips : J. Am. Chem. Soc., 73, 1061 (1951); *ibid.*, 75, 4092 (1953).

3) G.R. Barker, N.G. Luthy, M.M. Dhar : J. Chem. Soc., 1954, 4206.